跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NAT-EVEROLIMUS - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NAT-EVEROLIMUS
Authorized
STANDARD
NAT-EVEROLIMUS
natco pharma (canada) inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
80f627f737aa7d6e
Company
natco pharma (canada) inc
Type
Standard
Approval Details
Approval Id
80f627f737aa7d6e
Drug Approval Canada Name
NAT-EVEROLIMUS
Product Name
NAT-EVEROLIMUS
Status
Marketed
Status Date
2023-04-05
Original Market Date
2023-04-05
Din
02530104
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L04AH02 EVEROLIMUS
Atc Name
l 04 ah 02
Aig Number
0152682001
Company Name
natco pharma (canada) inc
Company Address
2000 Argentia Road, Plaza 1, Suite 200, Mississauga, Ontario, Canada, L5N 1P7
Active Ingredients
EVEROLIMUS
5 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
80f627f737aa7d6e
Type
Standard
Back to Health Canada Approvals